Selective Α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson’s Disease

Molecular Therapy - United States
doi 10.1016/j.ymthe.2017.11.015
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Α-Synuclein: A Therapeutic Target for Parkinson’s Disease?

Pharmacological Research
Pharmacology
2008English

Lack of Pathogenic Potential of Peripheral Α-Synuclein Aggregates From Parkinson’s Disease Patients

Acta neuropathologica communications
Forensic MedicineMolecular NeurosciencePathologyNeurologyCellular
2018English

Correction: Targeting the Intrinsically Disordered Structural Ensemble of Α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease

PLoS ONE
Multidisciplinary
2014English

Α-Synuclein and Anti-Α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls

PLoS ONE
Multidisciplinary
2012English

The Cell-Death-Associated Polymer PAR Feeds Forward Α-Synuclein Toxicity in Parkinson’s Disease

Molecular Cell
Cell BiologyMolecular Biology
2019English

The Role of Lipids Interacting With Α-Synuclein in the Pathogenesis of Parkinson’s Disease

Journal of Parkinson's Disease
Molecular NeuroscienceNeurologyCellular
2017English

Elevated Serum Α-Synuclein Autoantibodies in Patients With Parkinson’s Disease Relative to Alzheimer’s Disease and Controls

Frontiers in Neurology
Neurology
2017English

Parkinson’s Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on Α-Synuclein

Neuron
Neuroscience
2015English

Parkinson’s Disease: Assay of Phosphorylated Α-Synuclein in Skin Biopsy for Early Diagnosis and Association With Melanoma

Brain Sciences
Neuroscience
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy